Perspectives on Newly Diagnosed Myeloma Treatment and Emerging Challenges.
IF 11.5
Q1 HEMATOLOGY
引用次数: 0
Abstract
This commentary explores new challenges in the management of newly diagnosed multiple myeloma and strategies for sustaining improvements in patient outcomes. We highlight the need for risk-adapted approaches, the potential future incorporation of T cell-redirecting immunotherapies in first-line treatment, and the challenge of access to care.
新诊断的骨髓瘤治疗和新出现的挑战的观点。
这篇评论探讨了新诊断多发性骨髓瘤管理的新挑战和持续改善患者预后的策略。我们强调了风险适应方法的必要性，T细胞重定向免疫疗法在一线治疗中的潜在未来结合，以及获得护理的挑战。
本文章由计算机程序翻译，如有差异，请以英文原文为准。
求助全文
约1分钟内获得全文
求助全文
来源期刊
Blood Cancer Discovery
Multiple-
CiteScore
12.70
自引率
1.80%
发文量
139
期刊介绍：
The journal Blood Cancer Discovery publishes high-quality Research Articles and Briefs that focus on major advances in basic, translational, and clinical research of leukemia, lymphoma, myeloma, and associated diseases. The topics covered include molecular and cellular features of pathogenesis, therapy response and relapse, transcriptional circuits, stem cells, differentiation, microenvironment, metabolism, immunity, mutagenesis, and clonal evolution. These subjects are investigated in both animal disease models and high-dimensional clinical data landscapes.
The journal also welcomes submissions on new pharmacological, biological, and living cell therapies, as well as new diagnostic tools. They are interested in prognostic, diagnostic, and pharmacodynamic biomarkers, and computational and machine learning approaches to personalized medicine. The scope of submissions ranges from preclinical proof of concept to clinical trials and real-world evidence.
Blood Cancer Discovery serves as a forum for diverse ideas that shape future research directions in hematooncology. In addition to Research Articles and Briefs, the journal also publishes Reviews, Perspectives, and Commentaries on topics of broad interest in the field.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
